



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/320,609	05/26/1999	JEFFREY WILUSZ	601-1-088N	4962

7590 12/17/2001

KLAUBER & JACKSON
411 HACKENSACK AVENUE
HACKENSACK, NJ 07601

EXAMINER

MORAN, MARJORIE A

ART UNIT	PAPER NUMBER
----------	--------------

1631

DATE MAILED: 12/17/2001

17

Please find below and/or attached an Office communication concerning this application or proceeding.

Interview Summary

Application No.

09/320,609

Applicant(s)

WILUSZ ET AL.

Examiner

Marjorie A. Moran

Art Unit

1631

All participants (applicant, applicant's representative, PTO personnel):

(1) Marjorie A. Moran.(3) Dr. Wilusz.(2) Catherine Smith.

(4) _____.

Date of Interview: 11 December 2001 .

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.

If Yes, brief description: _____ .

Claim(s) discussed: 1 .

Identification of prior art discussed: BERNSTEIN, LEVY (1996 and 1998) .

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.


Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet .

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) ☐ It is not necessary for applicant to provide a separate record of the substance of the interview(if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Dr. Wilusz described the inventive system as one which faithfully reproduces mRNA turnover; wherein a polyA tail is first shortened by specific exonucleases, then the body of the mRNA is quickly degraded. This system allows for deadenylation and degradation by specific ribonucleases with minimal "garbage" degradation and very good reproducibility. Dr. Wilusz stated that his system has been and is being used successfully in a variety of applications. With regard to the prior art, Dr. Wilusz stated that BERNSTEIN's mRNA does not have a true polyA tail as "extra" residues are present at the end of the polyA portion, therefore BERNSTEIN does not teach "true" deadenylation. The examiner stated that in the absence of evidence to the contrary, she considered a teaching for mRNA (e.g. by BERNSTEIN) to be a teaching for a typical mRNA; e.g. with a polyA tail. Ms. Smith and Dr. Wilusz, as previously argued, maintained that BERNSTEIN does not teach use of a supernatant fraction, specifically a cytoplasmic fraction. The examiner maintained that BERNSTEIN teaches at least a supernatant fraction, which in combination with LEVY, makes use of a cytoplasmic fraction obvious. Dr. Wilusz argued that LEVY also does not teach deadenylation as LEVY's RNA's do not have a "true" polyA tail, and argued that neither BERNSTEIN nor LEVY teach the specific ribonucleases necessary for "regulated" deadenylation. The examiner pointed out that the claims are not limited to an RNA with a "true" polyA tail (e.g. an mRNA with an uncapped polyA tail), or are they limited to any specific ribonuclease. The examiner stated that both BERNSTEIN and LEVY teach deadenylation and degradation of RNA's, and therefore maintained that they read on the instant claims, specifically claim 1. Ms. Smith stated that the claims would be reviewed with these statements in mind. .